


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Prospect Waterbury, Inc. d/b/a The Waterbury Hospital</p> <p>2. 64 Robbins Street Waterbury, CT 06721</p>		<p>In accordance with letter dated October 30, 2020,</p>	<p>4. Expiration Date: March 31, 2026</p>
		<p>3. License No.: 06-02406-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01251 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.500</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Isotope Products Laboratories, Model NES-8412; North American Scientific, Inc., Model MED 3601)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 2.5 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.</p> <p>D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 06-02406-01

Docket or Reference No.:  
030-01251

Amendment No. 77

CONDITIONS

10. Licensed material listed in Subitem Nos. 6A through 6D shall be used at the licensee's facilities located at  
 A. 455 Chase Parkway, Waterbury, Connecticut  
 B. 64 Robbins Street, Waterbury, Connecticut
11. The Radiation Safety Officer (RSO) for this license is William J. Roch.
12. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Kenneth S. Allen, M.D.

Ehsan Ansari, M.D.

Duncan Belcher, M.D.

Jeffrey A. Bitterman, M.D.

Brian Girard, D.O.

Douglas Housman, M.D.

Eric A. Hyson, M.D.

Kevin G. Kett, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.500

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

Oral administration of sodium iodide I-131

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.500; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 06-02406-01

Docket or Reference No.:  
030-01251

Amendment No. 77

Authorized Users

Andrew Lawson, M.D.

Joseph Ravalese, III, M.D.

Mark L. Ruggiero, M.D.

Marco Verga, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries, Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

10 CFR 35.300

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated November 23, 2015 [ML15338A022]
- B. Letter dated February 4, 2016 [ML16076A127]
- C. Letter dated March 3, 2016 [ML16076A175]
- D. Letter dated June 30, 2016 [ML16193A035]
- E. Letter dated September 29, 2016 [ML16274A110]
- F. Letter dated October 5, 2016 [ML16286A581]
- G. Letter dated November 10, 2016 [ML16337A011] continued

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 06-02406-01

Docket or Reference No.:  
030-01251

Amendment No. 77

- H. Letter dated July 10, 2018 [ML18207A645]
- I. Letter dated August 17, 2018 [ML18247A210]
- J. Letter dated October 17, 2018 [ML18297A231]
- K. Letter dated December 14, 2018 [ML19008A110]
- L. Letter dated December 9, 2020 [ML20350B400]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 17, 2020

By: \_\_\_\_\_

Robin Elliott  
Region 1